NCT00726180终止1 期
Evaluation of the Use of Trastuzumab to Induce Increased ER Expression in ER-Negative/Low, Her-2/Neu Positive Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Standard Immunohistochemistry and Allred Scores Were to be Used to Measure the Estrogen Receptor (ER) Response Rate in Patients With ER-negative/Low, and Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-positive Breast Cancer.
研究概览
简要总结
The majority pf breast cancers present as ER-positive, many of which are able to be targeted with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has the potential to benefit patients by making hormonal therapies a therapeutic option and possibly improving their overall prognosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women who have Her-2 positive and ER- negative or ER-low breast cancer that has not metastasized, or spread to other parts of the body, are eligible for the study.
- •Participants must have had either a core biopsy or incisional biopsy of their breast cancer, but not yet had definitive breast surgery, including lumpectomy or mastectomy.
- •Participants may not have had a BRCA mutation found on genetic testing.
- •Participants should have not yet received treatment for their breast cancer, including:
- •chemotherapy,
- •hormonal therapy,
- •trastuzumab.
排除标准
- 未提供
研究组 & 干预措施
Treatment arm
Experimental
干预措施: trastuzumab (Herceptin®) (Drug)
结局指标
主要结局
Standard Immunohistochemistry and Allred Scores Were to be Used to Measure the Estrogen Receptor (ER) Response Rate in Patients With ER-negative/Low, and Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-positive Breast Cancer.
时间窗: 90 days
次要结局
未报告次要终点
研究者
Ann Schott, MD
Associate Professor of Medicine
University of Michigan Rogel Cancer Center
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2Breast CancerHeart FailureNCT02907021Population Health Research Institute20
招募中
2 期
ATEMPT 2.0: Adjuvant T-DM1 vs THHER2-positive Breast CancerBreast CancerNCT04893109Dana-Farber Cancer Institute500
进行中（未招募）
4 期
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic TherapyBreast CancerNCT04928261Ottawa Hospital Research Institute52
终止
2 期
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor CellsBreast NeoplasmsNCT01779050Washington University School of Medicine7
进行中（未招募）
2 期
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerBreast CancerNCT03414658Adrienne G. Waks100